Dr. Yeh founded PharmaEngine, Inc. in Jan. 2003, and has served as President and Chief Executive Officer. She worked in academic research in England and France, as well as in drug discovery and development at T Cell Sciences, CytoMed, LeukoSite, and Millennium Pharmaceuticals in Cambridge, MA, USA. She is a successful advocate in building and leading multi-disciplinary teams and in creating development strategies and resource plans to allow accelerated regulatory approval. Over the past fifteen years, under her leadership PharmaEngine has achieved many important milestones, including FDA approval of its new drug, ONIVYDE. She received her Ph.D. in Immunology at the Medical University of South Carolina, Charleston, SC, USA.